RT @ollidufva: One more CRISPR screen study, this time to find resistance mechanisms to bispecific antibody immunotherapy: https://t.co/a9g…

One more CRISPR screen study, this time to find resistance mechanisms to bispecific antibody immunotherapy: https://t.co/a9ghVPibep 9/n

RT @CIR_AACR: Genome-wide #CRISPR screen developed to understand cancer cell-derived resistance mechanisms to CD3-#bispecific #antibodies.…

Genome-wide #CRISPR screen developed to understand cancer cell-derived resistance mechanisms to CD3-#bispecific #antibodies. @NovartisScience #flotetuzumab #CD123 https://t.co/jyi248QmTP https://t.co/hFOpG6wg1k

By assessing resistance to the clinical CD3-bispecific #antibody flotetuzumab, scientists identified core fucosylation as a critical pathway to regulate flotetuzumab binding to the CD123 #antigen. 📙 @CIR_AACR: https://t.co/bkpwN47JYv https://t.co/1VKT53na

#BispecificAntibodies are an emerging strategy for #cancer #immunotherapy being discussed at #SITC2020. These #CIR articles highlight their potential: https://t.co/kuAiZvmvgR https://t.co/w5YJA8wrhX https://t.co/0ZytAeMPMF https://t.co/R5TBfzlE5Q